Dr. Jon Wall: for cardiac #amyloidosis, being able to understand how the heart will respond to a treatment in a trial is also dependent upon appreciating what else is going on in the body. #AmyloidosisForum

Attralus receives FDA and EMA orphan designation for AT-01 as a #diagnostic for the management of ATTR and AL #amyloidosis. Read more @ ow.ly/QrZ850M6Vsg.

Future of cardiac amyloidosis diagnostics: #evuzamitide. Heart Failure Grand Rounds UH Harrington Heart & Vascular Institute University Hospitals Dr. Justin Grodin @JLGRodin

This is an interesting case published by mathew.maurer et al in Journal of Nuclear Cardiology 64 yo AA man, HCM hx, found + V122I. PYP -ve, CMR no LGE. AL w/u -ve. EMBx confirmed ATTR-CM. Underwent AT-01 (I-124 evuzamitide) PET/CT which was positive. #CardioTwitter #CVNuc #Echofirst #WhyCMR

Fantastic talk by Sharmila Dorbala on #ThinkPET for Amyloid 🔹 Molecular tracers - direct🚦of amyloid fibril 🔹New tracer 124I-Evuzamitide in clinical trials 🔹Can quantify WB amyloid load 🔹Quantitative PET - possible role in amyloid depleting Rx Saurabh Malhotra ASNC Society #CVNuc

Check out this exciting new investigation into the performance of AT-01 (124I-evuzamitide) PET/CT and a comparison to 18F florbetapir by Sharmila Dorbala Sarah Cuddy et al. jacc.org/doi/10.1016/j.… #CardioTwitter #CVNuc

Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at #ASNC2023 Read more - attralus.com/press-releases… #amyloidosis

New Research: Development and characterization of a prototypic pan-amyloid clearing agent – a novel murine peptide-immunoglobulin fusion: Introduction Systemic amyloidosis is a progressive disorder characterized by the extracellular… #immunology frontiersin.org/articles/10.33…

Packed house for the Amyloidosis Support ATTR meeting in Chicago. Congrats on another great meeting Muriel Finkel !

Cardiac Amyloid Detection by PET/CT Imaging of Iodine (124I) Evuzamitide in systemic #amyloidosis sciencedirect.com/science/articl…

Have you heard of iodine (124I) evuzamitide (124I-P5+14)? Two papers show that this might be the next big thing for the imaging of cardiac amyloidosis.

Iodine (124I) evuzamitide is a #ThinkPET #radiotracer for #amyloidosis imaging with high sensitivity. In this #JACCIMG Phase I/II study, there was potential for early, presymptomatic disease detection throughout the body. bit.ly/3FQ9Mzf #cvPET #cvImaging @EM4Research

Attralus is excited to announce that we have received Breakthrough Therapy Designation for our pan-amyloid diagnostic PET imaging candidate I124-evuzamitide (AT-01) for cardiac #amyloidosis. Read the press release: attralus.com/press-releases….

Excellent news. I-124 evuzamitide is one of the major and important developments in the systemic amyloidosis space

Encouraged that the U.S. FDA has recognized the tremendous need and the role that diagnostics can play in improving outcomes for #amyloidosis patients. ⚕️🚨 Physicians: Recruitment of patients w/suspected cardiac amyloidosis in the planned Phase 3 study of AT-01 will be critical!

Attralus Great news and look forward to the studies of this potentially paradigm changing tracer in amyloid diagnosis and management

Attralus Congratulations Spencer and Attralus Team! Noninvasive molecular diagnosis of cardiac amyloidosis is crucial for early diagnosis and effective therapy. Excited to serve as PI of the Phase 3 study REVEAL-Research with EVuzamitide to Elucidate cardiac AmyLoidosis.

In case you missed it - a phase III trial of I-124 evuzamitide for the diagnosis of cardiac amyloidosis will kick off in early 2025 #CVNuc #CardioTwitter

Fantastic work by Jon Wall, Emily Martin et al SPECT & PET tracers have different pros/cons But this is a definite advancement in the field. Meanwhile, we are starting our REVEAL pIII trial of evuzamitide PET Sharmila Dorbala #CardioTwitter #CVNuc #ASNC2024

Attralus receives Orphan Drug Designation from U.S. FDA for AT-02 for the treatment of ATTR #amyloidosis. Read the press release: attralus.com/press-releases…